You are viewing the site in preview mode

Skip to main content

Advertisement

Table 2 Estimated effectiveness of the pandemic influenza vaccine during the main wave of the influenza pandemic in Norway.

From: Usefulness of health registries when estimating vaccine effectiveness during the influenza A(H1N1)pdm09 pandemic in Norway

Week 44 45 46 47 48 49 50 51 52 53
Vaccinated population  
No of cases 3 40 45 31 21 7 5 1 1 3
Population 32,766 266,276 501,087 697,952 873,561 1,105,676 1,397,413 1,675,256 1,891,882 1,891,654
Incidence(per 100,000) 9.16 15.02 8.98 4.44 2.40 0.63 0.36 0.06 0.05 0.16
Unvaccinated population  
No of cases 2683 2540 1,581 854 449 182 80 33 16 12
Population 4,811,608 4,575,412 4,338,021 4,139,530 3,963,036 3,730,451 3,438,525 3,160,597 2,943,937 2,919,148
Incidence(per 100,000) 55.76 55.51 36.45 20.63 11.33 4.88 2.33 1.04 0.54 0.41
Vaccine effectiveness  
Point estimate 84% 73% 75% 78% 79% 87% 85% 94% 90% 62%
95% confidence interval 50%-95% 63%-80% 67%-82% 69%-85% 68%-86% 72%-99% 62%-94% 58%-99% 27%-99% -34%-90%
  1. Estimated effectiveness of AS03-adjuvanted monovalent vaccine during the main wave (weeks 44-53, 2009) of the influenza pandemic in Norway. Vaccinees were considered immune eight days and later after vaccination.